Table of Content

1 Neuromuscular Blocking Drug Market Overview
1.1 Product Overview and Scope of Neuromuscular Blocking Drug
1.2 Neuromuscular Blocking Drug Segment by Type
1.2.1 Global Neuromuscular Blocking Drug Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Non-polarizing Agents
1.2.3 Depolarizing Agents
1.3 Neuromuscular Blocking Drug Segment by Application
1.3.1 Neuromuscular Blocking Drug Sales Comparison by Application: (2021-2027)
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.3.5 Others
1.4 Global Neuromuscular Blocking Drug Market Size Estimates and Forecasts
1.4.1 Global Neuromuscular Blocking Drug Revenue 2016-2027
1.4.2 Global Neuromuscular Blocking Drug Sales 2016-2027
1.4.3 Neuromuscular Blocking Drug Market Size by Region: 2016 Versus 2021 Versus 2027

2 Neuromuscular Blocking Drug Market Competition by Manufacturers
2.1 Global Neuromuscular Blocking Drug Sales Market Share by Manufacturers (2016-2021)
2.2 Global Neuromuscular Blocking Drug Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Neuromuscular Blocking Drug Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Neuromuscular Blocking Drug Manufacturing Sites, Area Served, Product Type
2.5 Neuromuscular Blocking Drug Market Competitive Situation and Trends
2.5.1 Neuromuscular Blocking Drug Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Neuromuscular Blocking Drug Players Market Share by Revenue
2.5.3 Global Neuromuscular Blocking Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Neuromuscular Blocking Drug Retrospective Market Scenario by Region
3.1 Global Neuromuscular Blocking Drug Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Neuromuscular Blocking Drug Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Neuromuscular Blocking Drug Market Facts & Figures by Country
3.3.1 North America Neuromuscular Blocking Drug Sales by Country
3.3.2 North America Neuromuscular Blocking Drug Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Neuromuscular Blocking Drug Market Facts & Figures by Country
3.4.1 Europe Neuromuscular Blocking Drug Sales by Country
3.4.2 Europe Neuromuscular Blocking Drug Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Neuromuscular Blocking Drug Market Facts & Figures by Region
3.5.1 Asia Pacific Neuromuscular Blocking Drug Sales by Region
3.5.2 Asia Pacific Neuromuscular Blocking Drug Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Neuromuscular Blocking Drug Market Facts & Figures by Country
3.6.1 Latin America Neuromuscular Blocking Drug Sales by Country
3.6.2 Latin America Neuromuscular Blocking Drug Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Neuromuscular Blocking Drug Market Facts & Figures by Country
3.7.1 Middle East and Africa Neuromuscular Blocking Drug Sales by Country
3.7.2 Middle East and Africa Neuromuscular Blocking Drug Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 UAE
4 Global Neuromuscular Blocking Drug Historic Market Analysis by Type
4.1 Global Neuromuscular Blocking Drug Sales Market Share by Type (2016-2021)
4.2 Global Neuromuscular Blocking Drug Revenue Market Share by Type (2016-2021)
4.3 Global Neuromuscular Blocking Drug Price by Type (2016-2021)

5 Global Neuromuscular Blocking Drug Historic Market Analysis by Application
5.1 Global Neuromuscular Blocking Drug Sales Market Share by Application (2016-2021)
5.2 Global Neuromuscular Blocking Drug Revenue Market Share by Application (2016-2021)
5.3 Global Neuromuscular Blocking Drug Price by Application (2016-2021)

6 Key Companies Profiled
6.1 Hikma Pharmaceuticals
6.1.1 Hikma Pharmaceuticals Corporation Information
6.1.2 Hikma Pharmaceuticals Description and Business Overview
6.1.3 Hikma Pharmaceuticals Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Hikma Pharmaceuticals Product Portfolio
6.1.5 Hikma Pharmaceuticals Recent Developments/Updates
6.2 Merck
6.2.1 Merck Corporation Information
6.2.2 Merck Description and Business Overview
6.2.3 Merck Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Merck Product Portfolio
6.2.5 Merck Recent Developments/Updates
6.3 Novartis
6.3.1 Novartis Corporation Information
6.3.2 Novartis Description and Business Overview
6.3.3 Novartis Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
6.3.4 Novartis Product Portfolio
6.3.5 Novartis Recent Developments/Updates
6.4 Bayer
6.4.1 Bayer Corporation Information
6.4.2 Bayer Description and Business Overview
6.4.3 Bayer Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Bayer Product Portfolio
6.4.5 Bayer Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Corporation Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Pfizer Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 AbbVie
6.6.1 AbbVie Corporation Information
6.6.2 AbbVie Description and Business Overview
6.6.3 AbbVie Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
6.6.4 AbbVie Product Portfolio
6.6.5 AbbVie Recent Developments/Updates
6.7 GSK
6.6.1 GSK Corporation Information
6.6.2 GSK Description and Business Overview
6.6.3 GSK Neuromuscular Blocking Drug Sales, Revenue and Gross Margin (2016-2021)
6.4.4 GSK Product Portfolio
6.7.5 GSK Recent Developments/Updates

7 Neuromuscular Blocking Drug Manufacturing Cost Analysis
7.1 Neuromuscular Blocking Drug Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Neuromuscular Blocking Drug
7.4 Neuromuscular Blocking Drug Industrial Chain Analysis

8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Neuromuscular Blocking Drug Distributors List
8.3 Neuromuscular Blocking Drug Customers

9 Neuromuscular Blocking Drug Market Dynamics
9.1 Neuromuscular Blocking Drug Industry Trends
9.2 Neuromuscular Blocking Drug Growth Drivers
9.3 Neuromuscular Blocking Drug Market Challenges
9.4 Neuromuscular Blocking Drug Market Restraints

10 Global Market Forecast
10.1 Neuromuscular Blocking Drug Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Neuromuscular Blocking Drug by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Neuromuscular Blocking Drug by Type (2022-2027)
10.2 Neuromuscular Blocking Drug Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Neuromuscular Blocking Drug by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Neuromuscular Blocking Drug by Application (2022-2027)
10.3 Neuromuscular Blocking Drug Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Neuromuscular Blocking Drug by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Neuromuscular Blocking Drug by Region (2022-2027)

11 Research Finding and Conclusion

12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer

List of Figure

List of Tables
Table 1. Global Neuromuscular Blocking Drug Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Neuromuscular Blocking Drug Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global Neuromuscular Blocking Drug Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Neuromuscular Blocking Drug Covered in This Study
Table 5. Global Neuromuscular Blocking Drug Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global Neuromuscular Blocking Drug Sales Share by Manufacturers (2016-2021)
Table 7. Global Neuromuscular Blocking Drug Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Neuromuscular Blocking Drug Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Neuromuscular Blocking Drug Average Price (US$/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Neuromuscular Blocking Drug Manufacturing Sites and Area Served
Table 11. Manufacturers Neuromuscular Blocking Drug Product Type
Table 12. Global Neuromuscular Blocking Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Neuromuscular Blocking Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Neuromuscular Blocking Drug as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Neuromuscular Blocking Drug Sales by Region (2016-2021) & (K Units)
Table 16. Global Neuromuscular Blocking Drug Sales Market Share by Region (2016-2021)
Table 17. Global Neuromuscular Blocking Drug Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Neuromuscular Blocking Drug Sales by Country (2016-2021) & (K Units)
Table 19. North America Neuromuscular Blocking Drug Sales Market Share by Country (2016-2021)
Table 20. North America Neuromuscular Blocking Drug Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Neuromuscular Blocking Drug Revenue Market Share by Country (2016-2021)
Table 22. Europe Neuromuscular Blocking Drug Sales by Country (2016-2021) & (K Units)
Table 23. Europe Neuromuscular Blocking Drug Sales Market Share by Country (2016-2021)
Table 24. Europe Neuromuscular Blocking Drug Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Neuromuscular Blocking Drug Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Neuromuscular Blocking Drug Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific Neuromuscular Blocking Drug Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Neuromuscular Blocking Drug Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Neuromuscular Blocking Drug Revenue Market Share by Region (2016-2021)
Table 30. Latin America Neuromuscular Blocking Drug Sales by Country (2016-2021) & (K Units)
Table 31. Latin America Neuromuscular Blocking Drug Sales Market Share by Country (2016-2021)
Table 32. Latin America Neuromuscular Blocking Drug Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Neuromuscular Blocking Drug Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Neuromuscular Blocking Drug Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa Neuromuscular Blocking Drug Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Neuromuscular Blocking Drug Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Neuromuscular Blocking Drug Revenue Market Share by Country (2016-2021)
Table 38. Global Neuromuscular Blocking Drug Sales (K Units) by Type (2016-2021)
Table 39. Global Neuromuscular Blocking Drug Sales Market Share by Type (2016-2021)
Table 40. Global Neuromuscular Blocking Drug Revenue (Million US$) by Type (2016-2021)
Table 41. Global Neuromuscular Blocking Drug Revenue Share by Type (2016-2021)
Table 42. Global Neuromuscular Blocking Drug Price (US$/Unit) by Type (2016-2021)
Table 43. Global Neuromuscular Blocking Drug Sales (K Units) by Application (2016-2021)
Table 44. Global Neuromuscular Blocking Drug Sales Market Share by Application (2016-2021)
Table 45. Global Neuromuscular Blocking Drug Revenue (Million US$) by Application (2016-2021)
Table 46. Global Neuromuscular Blocking Drug Revenue Share by Application (2016-2021)
Table 47. Global Neuromuscular Blocking Drug Price (US$/Unit) by Application (2016-2021)
Table 48. Hikma Pharmaceuticals Corporation Information
Table 49. Hikma Pharmaceuticals Description and Business Overview
Table 50. Hikma Pharmaceuticals Neuromuscular Blocking Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 51. Hikma Pharmaceuticals Neuromuscular Blocking Drug Product
Table 52. Hikma Pharmaceuticals Recent Developments/Updates
Table 53. Merck Corporation Information
Table 54. Merck Description and Business Overview
Table 55. Merck Neuromuscular Blocking Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 56. Merck Neuromuscular Blocking Drug Product
Table 57. Merck Recent Developments/Updates
Table 58. Novartis Corporation Information
Table 59. Novartis Description and Business Overview
Table 60. Novartis Neuromuscular Blocking Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 61. Novartis Neuromuscular Blocking Drug Product
Table 62. Novartis Recent Developments/Updates
Table 63. Bayer Corporation Information
Table 64. Bayer Description and Business Overview
Table 65. Bayer Neuromuscular Blocking Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 66. Bayer Neuromuscular Blocking Drug Product
Table 67. Bayer Recent Developments/Updates
Table 68. Pfizer Corporation Information
Table 69. Pfizer Description and Business Overview
Table 70. Pfizer Neuromuscular Blocking Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 71. Pfizer Neuromuscular Blocking Drug Product
Table 72. Pfizer Recent Developments/Updates
Table 73. AbbVie Corporation Information
Table 74. AbbVie Description and Business Overview
Table 75. AbbVie Neuromuscular Blocking Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 76. AbbVie Neuromuscular Blocking Drug Product
Table 77. AbbVie Recent Developments/Updates
Table 78. GSK Corporation Information
Table 79. GSK Description and Business Overview
Table 80. GSK Neuromuscular Blocking Drug Sales (K Units), Revenue (Million US$), Price (US$/Unit) and Gross Margin (2016-2021)
Table 81. GSK Neuromuscular Blocking Drug Product
Table 82. GSK Recent Developments/Updates
Table 83. Production Base and Market Concentration Rate of Raw Material
Table 84. Key Suppliers of Raw Materials
Table 85. Neuromuscular Blocking Drug Distributors List
Table 86. Neuromuscular Blocking Drug Customers List
Table 87. Neuromuscular Blocking Drug Market Trends
Table 88. Neuromuscular Blocking Drug Growth Drivers
Table 89. Neuromuscular Blocking Drug Market Restraints
Table 90. Global Neuromuscular Blocking Drug Sales Forecast by Type (2022-2027) & (K Units)
Table 91. Global Neuromuscular Blocking Drug Sales Market Share Forecast by Type (2022-2027)
Table 92. Global Neuromuscular Blocking Drug Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 93. Global Neuromuscular Blocking Drug Revenue Market Share Forecast by Type (2022-2027)
Table 94. Global Neuromuscular Blocking Drug Sales Forecast by Application (2022-2027) & (K Units)
Table 95. Global Neuromuscular Blocking Drug Sales Market Share Forecast by Application (2022-2027)
Table 96. Global Neuromuscular Blocking Drug Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 97. Global Neuromuscular Blocking Drug Revenue Market Share Forecast by Application (2022-2027)
Table 98. Global Neuromuscular Blocking Drug Sales Forecast by Region (2022-2027) & (K Units)
Table 99. Global Neuromuscular Blocking Drug Sales Market Share Forecast by Region (2022-2027)
Table 100. Global Neuromuscular Blocking Drug Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 101. Global Neuromuscular Blocking Drug Revenue Market Share Forecast by Region (2022-2027)
Table 102. Research Programs/Design for This Report
Table 103. Key Data Information from Secondary Sources
Table 104. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Neuromuscular Blocking Drug
Figure 2. Global Neuromuscular Blocking Drug Market Share by Type in 2020 & 2027
Figure 3. Non-polarizing Agents Product Picture
Figure 4. Depolarizing Agents Product Picture
Figure 5. Global Neuromuscular Blocking Drug Market Share by Application in 2020 & 2027
Figure 6. Hospital Pharmacy
Figure 7. Retail Pharmacy
Figure 8. Online Pharmacy
Figure 9. Others
Figure 10. Global Neuromuscular Blocking Drug Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Neuromuscular Blocking Drug Market Size 2016-2027 (US$ Million)
Figure 12. Global Neuromuscular Blocking Drug Sales 2016-2027 (K Units)
Figure 13. Global Neuromuscular Blocking Drug Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 14. Neuromuscular Blocking Drug Sales Share by Manufacturers in 2020
Figure 15. Global Neuromuscular Blocking Drug Revenue Share by Manufacturers in 2020
Figure 16. The Global 5 and 10 Largest Neuromuscular Blocking Drug Players: Market Share by Revenue in 2020
Figure 17. Neuromuscular Blocking Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 18. Global Neuromuscular Blocking Drug Sales Market Share by Region (2016-2021)
Figure 19. Global Neuromuscular Blocking Drug Sales Market Share by Region in 2020
Figure 20. Global Neuromuscular Blocking Drug Revenue Market Share by Region (2016-2021)
Figure 21. Global Neuromuscular Blocking Drug Revenue Market Share by Region in 2020
Figure 22. U.S. Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Canada Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Germany Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. France Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. U.K. Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Italy Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Russia Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. China Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Japan Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. South Korea Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. India Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Australia Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Taiwan Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Indonesia Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Thailand Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Malaysia Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Philippines Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Vietnam Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Mexico Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Brazil Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Argentina Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Turkey Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Saudi Arabia Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. UAE Neuromuscular Blocking Drug Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Sales Market Share of Neuromuscular Blocking Drug by Type (2016-2021)
Figure 47. Sales Market Share of Neuromuscular Blocking Drug by Application (2016-2021)
Figure 48. Sales Market Share of Neuromuscular Blocking Drug by Application in 2020
Figure 49. Revenue Share of Neuromuscular Blocking Drug by Application (2016-2021)
Figure 50. Revenue Share of Neuromuscular Blocking Drug by Application in 2020
Figure 51. Manufacturing Cost Structure of Neuromuscular Blocking Drug
Figure 52. Manufacturing Process Analysis of Neuromuscular Blocking Drug
Figure 53. Neuromuscular Blocking Drug Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed